Ana Sayfa İlaç Rusya ilaç pazarında kartelleşme mi var?

Rusya ilaç pazarında kartelleşme mi var?

Rusya Federal Anti-Tekel Servisi (FAS), ülkenin devlet ilaçları tedarikçilerinden biri olan R-Pharm’ın, ülkenin Sağlık Bakanlığı ile yasadışı bir şekilde bir araya gelmesinden şüpheleniyor

According to the FAS, the Ministry of Health may be involved in the provision advantages to R-Pharm during state tenders for the purchase of drugs for state needs. Among these drugs are preparations against HIV, hepatitis B and C viruses, multidrug-resistant tuberculosis, and other antiviral and antibacterial drugs.

In addition, according to data from the FAS, R-Pharm violated contracts on the sum of 8 billion roubles (~$138 million), but was not disqualified from bidding.

According to a source close to the FAS, in 2017 R-Pharm violated 19 contracts for public procurements in Russia. According to him, for such violations, the company must be entered in the register of unscrupulous suppliers, but R-Pharm continues to participate in the tenders.

“The company can be included in the register of unscrupulous suppliers for public procurements if it won the bidding but avoids signing of the contract, and if the contract with it is terminated by a court decision or if the refusal to perform the contract is fixed,” a senior lawyer at Baker & McKenzie, Sergei Lomakin, explains. That will mean the company will not be able to participate in the tenders for two years.

If the R-Pharm is included in such a register and will lose the right to participate in the bidding, the Ministry of Health may face with certain problems as the company has a significant share in the Russian public procurement market. That may also lead to a shortage of drugs in Russia.